GSK's price cut plan lacks clarity, say Indian generic firms
This article was originally published in Scrip
Executive Summary
Indian generic drug companies are viewing GlaxoSmithKline's recent announcement to cut the prices of its medicines in 50 least developed countries with some scepticism and claim that these plans lack clarity.